These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
665 related articles for article (PubMed ID: 7541742)
1. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742 [TBL] [Abstract][Full Text] [Related]
2. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981 [TBL] [Abstract][Full Text] [Related]
3. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383 [TBL] [Abstract][Full Text] [Related]
4. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Pujol JL; Grenier J; Parrat E; Lehmann M; Lafontaine T; Quantin X; Michel FB Am J Respir Crit Care Med; 1996 Sep; 154(3 Pt 1):725-33. PubMed ID: 8810612 [TBL] [Abstract][Full Text] [Related]
5. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607 [TBL] [Abstract][Full Text] [Related]
6. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Rastel D; Ramaioli A; Cornillie F; Thirion B Eur J Cancer; 1994; 30A(5):601-6. PubMed ID: 7521651 [TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer. Maeda Y; Segawa Y; Takigawa N; Takata I; Fujimoto N Intern Med; 1996 Oct; 35(10):764-71. PubMed ID: 8933183 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. Niklinski J; Furman M; Chyczewska E; Chyczewski L; Rogowski F; Laudanski J Eur Respir J; 1995 Feb; 8(2):291-4. PubMed ID: 7538933 [TBL] [Abstract][Full Text] [Related]
9. Cytokeratin fragment 19 (CYFRA 21-1) as a tumor marker in non-small cell lung cancer. Huang MS; Jong SB; Lin MS; Chong IW; Tsai MS; Lin HC; Hwang JJ Kaohsiung J Med Sci; 1996 Feb; 12(2):62-8. PubMed ID: 8709175 [TBL] [Abstract][Full Text] [Related]
10. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. van der Gaast A; Schoenmakers CH; Kok TC; Blijenberg BG; Cornillie F; Splinter TA Br J Cancer; 1994 Mar; 69(3):525-8. PubMed ID: 7510117 [TBL] [Abstract][Full Text] [Related]
12. Assessment of serum CYFRA 21-1 in lung cancer. Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502 [TBL] [Abstract][Full Text] [Related]
13. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Pujol JL; Boher JM; Grenier J; Quantin X Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Bréchot JM; Chevret S; Nataf J; Le Gall C; Frétault J; Rochemaure J; Chastang C Eur J Cancer; 1997 Mar; 33(3):385-91. PubMed ID: 9155521 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cyfra 21-1 as a marker for lung cancer. Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188 [TBL] [Abstract][Full Text] [Related]
16. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852 [TBL] [Abstract][Full Text] [Related]
17. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815 [TBL] [Abstract][Full Text] [Related]
18. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer. Chantapet P; Riantawan P; Lebnak P; Getngern P J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas. Karnak D; Ulubay G; Kayacan O; Beder S; Ibis E; Oflaz G Lung; 2001; 179(1):57-65. PubMed ID: 11479694 [TBL] [Abstract][Full Text] [Related]
20. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer. Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]